{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:48:11Z","timestamp":1760143691351,"version":"build-2065373602"},"reference-count":69,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.lpm.2014.02.030","type":"journal-article","created":{"date-parts":[[2014,7,11]],"date-time":"2014-07-11T16:30:50Z","timestamp":1405096250000},"page":"892-901","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Le topiramate a-t-il un int\u00e9r\u00eat en addictologie\u00a0?"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1319-9827","authenticated-orcid":false,"given":"Johan","family":"Cohen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5957-8948","authenticated-orcid":false,"given":"Alain","family":"Dervaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Laqueille","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lpm.2014.02.030_bib0005","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1001\/archpsyc.64.7.830","article-title":"Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions","volume":"64","author":"Hasin","year":"2007","journal-title":"Arch General Psychiatry"},{"key":"10.1016\/j.lpm.2014.02.030_bib0010","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.euroneuro.2011.07.018","article-title":"The size and burden of mental disorders and other disorders of the brain in Europe 2010","volume":"21","author":"Wittchen","year":"2011","journal-title":"Eur Neuro Psychopharmacol"},{"year":"2009","series-title":"Global health risks: mortality and burden of disease attributable to selected major risks","author":"WHO","key":"10.1016\/j.lpm.2014.02.030_bib0015"},{"key":"10.1016\/j.lpm.2014.02.030_bib0020","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/1874473711205010003","article-title":"Evidence-based pharmacological treatment of substance use disorders and pathological gambling","volume":"5","author":"van den Brink","year":"2012","journal-title":"Curr Drug Abuse Rev"},{"year":"2012","series-title":"FDA approves weight-management drug Qsymia","author":"FDA","key":"10.1016\/j.lpm.2014.02.030_bib0025"},{"key":"10.1016\/j.lpm.2014.02.030_bib0030","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.2174\/138161210791516404","article-title":"Topiramate in the new generation of drugs: efficacy in the treatment of alcoholic patients","volume":"16","author":"Johnson","year":"2010","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.lpm.2014.02.030_bib0035","doi-asserted-by":"crossref","first-page":"480","DOI":"10.2515\/therapie\/2012063","article-title":"Supervised off-label prescribing of topiramate for binge eating disorder within the system CAMTEA","volume":"67","author":"Guardia","year":"2012","journal-title":"Therapie"},{"key":"10.1016\/j.lpm.2014.02.030_bib0040","doi-asserted-by":"crossref","first-page":"634","DOI":"10.4088\/JCP.08r04062gry","article-title":"Topiramate in the treatment of substance-related disorders: a critical review of the literature","volume":"71","author":"Shinn","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.lpm.2014.02.030_bib0045","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1159\/000320471","article-title":"Topiramate for the treatment of alcohol dependence: comparison with naltrexone","volume":"17","author":"Florez","year":"2011","journal-title":"Eur Addict Res"},{"key":"10.1016\/j.lpm.2014.02.030_bib0050","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1471-244X-11-41","article-title":"Treatment of alcohol dependence with low-dose topiramate: an open-label controlled study","volume":"11","author":"Paparrigopoulos","year":"2011","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.lpm.2014.02.030_bib0055","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/JCP.0b013e3181bfdb79","article-title":"Modulation of impulsivity by topiramate: implications for the treatment of alcohol dependence","volume":"29","author":"Rubio","year":"2009","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.lpm.2014.02.030_bib0060","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.biopsych.2012.05.032","article-title":"Extended-release mixed amphetamine salts and topiramate for cocaine dependence: a randomized controlled trial","volume":"72","author":"Mariani","year":"2012","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.lpm.2014.02.030_bib0065","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1001\/jamapsychiatry.2013.2295","article-title":"Topiramate for the treatment of cocaine addiction: a randomized clinical trial","volume":"70","author":"Johnson","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.lpm.2014.02.030_bib0070","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.drugalcdep.2013.05.026","article-title":"A double-blind, placebo-controlled trial of topiramate for the treatment of comorbid cocaine and alcohol dependence","volume":"133","author":"Kampman","year":"2013","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.lpm.2014.02.030_bib0075","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1111\/j.1360-0443.2011.03771.x","article-title":"Topiramate for the treatment of methamphetamine addiction: a multi-center placebo-controlled trial","volume":"107","author":"Elkashef","year":"2012","journal-title":"Addiction"},{"key":"10.1016\/j.lpm.2014.02.030_bib0080","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.drugalcdep.2012.10.009","article-title":"Fine-grain analysis of the treatment effect of topiramate on methamphetamine addiction with latent variable analysis","volume":"130","author":"Ma","year":"2013","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.lpm.2014.02.030_bib0085","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.2174\/138161211796150828","article-title":"GABAergic and glutamatergic modulation in binge eating: therapeutic approach","volume":"17","author":"Guardia","year":"2011","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.lpm.2014.02.030_bib0090","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S0140-6736(03)13370-3","article-title":"Oral topiramate for treatment of alcohol dependence: a randomised controlled trial","volume":"361","author":"Johnson","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2014.02.030_bib0095","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1001\/archpsyc.61.9.905","article-title":"Oral topiramate reduces the consequences of drinking and improves the quality of life of alcohol-dependent individuals: a randomized controlled trial","volume":"61","author":"Johnson","year":"2004","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.lpm.2014.02.030_bib0100","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1001\/jama.298.14.1641","article-title":"Topiramate for treating alcohol dependence: a randomized controlled trial","volume":"298","author":"Johnson","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.lpm.2014.02.030_bib0105","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1001\/archinte.168.11.1188","article-title":"Improvement of physical health and quality of life of alcohol-dependent individuals with topiramate treatment: US multisite randomized controlled trial","volume":"168","author":"Johnson","year":"2008","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.lpm.2014.02.030_bib0110","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1111\/j.1360-0443.2008.02355.x","article-title":"Comparing topiramate with naltrexone in the treatment of alcohol dependence","volume":"103","author":"Baltieri","year":"2008","journal-title":"Addiction"},{"key":"10.1016\/j.lpm.2014.02.030_bib0115","first-page":"8","article-title":"Topiramate in the treatment of alcohol dependence: a meta-analysis","volume":"38","author":"Arbaizar","year":"2010","journal-title":"Actas Esp Psiquiatr"},{"key":"10.1016\/j.lpm.2014.02.030_bib0120","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1111\/j.1530-0277.2008.00680.x","article-title":"Using topiramate or naltrexone for the treatment of alcohol-dependent patients","volume":"32","author":"Florez","year":"2008","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.lpm.2014.02.030_bib0125","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jsat.2007.05.012","article-title":"An open randomized trial comparing disulfiram and topiramate in the treatment of alcohol dependence","volume":"34","author":"De Sousa","year":"2008","journal-title":"J Subst Abuse Treat"},{"key":"10.1016\/j.lpm.2014.02.030_bib0130","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1360-0443.2008.02148.x","article-title":"Preliminary evidence for gender-specific effects of topiramate as a potential aid to smoking cessation","volume":"103","author":"Anthenelli","year":"2008","journal-title":"Addiction"},{"key":"10.1016\/j.lpm.2014.02.030_bib0135","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.drugalcdep.2009.05.025","article-title":"Effects of topiramate or naltrexone on tobacco use among male alcohol-dependent outpatients","volume":"105","author":"Baltieri","year":"2009","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.lpm.2014.02.030_bib0140","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1001\/archinte.165.14.1600","article-title":"Use of oral topiramate to promote smoking abstinence among alcohol-dependent smokers: a randomized controlled trial","volume":"165","author":"Johnson","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.lpm.2014.02.030_bib0145","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.drugalcdep.2004.03.008","article-title":"A pilot trial of topiramate for the treatment of cocaine dependence","volume":"75","author":"Kampman","year":"2004","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.lpm.2014.02.030_bib0150","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.4088\/JCP.v64n1208","article-title":"Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, part 2: improvement in psychiatric measures","volume":"64","author":"Hedges","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.lpm.2014.02.030_bib0155","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.4088\/JCP.v64n1109","article-title":"Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, part 1: improvement in binge and purge measures","volume":"64","author":"Hoopes","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.lpm.2014.02.030_bib0160","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/eat.20202","article-title":"Topiramate treatment in bulimia nervosa patients: a randomized, double-blind, placebo-controlled trial","volume":"38","author":"Nickel","year":"2005","journal-title":"Int J Eat Disord"},{"key":"10.1016\/j.lpm.2014.02.030_bib0165","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1176\/appi.ajp.160.2.255","article-title":"Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial","volume":"160","author":"McElroy","year":"2003","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.lpm.2014.02.030_bib0170","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.biopsych.2006.08.008","article-title":"Topiramate for the treatment of binge eating disorder associated with obesity: a placebo-controlled study","volume":"61","author":"McElroy","year":"2007","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.lpm.2014.02.030_bib0175","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.4088\/JCP.v68n0901","article-title":"Double-blind, randomized, placebo-controlled trial of topiramate plus cognitive-behavior therapy in binge-eating disorder","volume":"68","author":"Claudino","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.lpm.2014.02.030_bib0180","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3109\/15622975.2011.560964","article-title":"A double-blind, placebo-controlled trial of topiramate for pathological gambling","volume":"14","author":"Berlin","year":"2013","journal-title":"World J Biol Psychiatry"},{"key":"10.1016\/j.lpm.2014.02.030_bib0185","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/01.wnf.0000152623.46474.07","article-title":"Topiramate versus fluvoxamine in the treatment of pathological gambling: a randomized, blind-rater comparison study","volume":"28","author":"Dannon","year":"2005","journal-title":"Clin Neuropharmacol"},{"year":"2011","series-title":"Mise en garde sur le d\u00e9tournement de l\u2019usage d\u2019Epitomax\u00ae \u00e0 vis\u00e9e amaigrissante en dehors des indications autoris\u00e9es","author":"ANSM","key":"10.1016\/j.lpm.2014.02.030_bib0190"},{"key":"10.1016\/j.lpm.2014.02.030_bib0195","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.ajo.2011.10.018","article-title":"Use of topiramate and risk of glaucoma: a case-control study","volume":"153","author":"Etminan","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.lpm.2014.02.030_bib0200","unstructured":"ClinicalTrials.gov. Identifier: NCT01135602. Topiramate for hospitalized patients with alcoholism: a 12-week study (THoPA-O). http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01135602; 2010. [Acc\u00e8s au site le 11\/06\/2014]."},{"key":"10.1016\/j.lpm.2014.02.030_bib0205","unstructured":"ClinicalTrials.gov Identifier: NCT01145677. Efficacy of topiramate for hospitalized patients with alcoholism (ETHoPA-R). http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01145677\u00a0; 2010 [Acc\u00e8s au site le 11\/06\/2014]."},{"key":"10.1016\/j.lpm.2014.02.030_bib0210","unstructured":"ClinicalTrials.gov Identifier: NCT00884884. Aripiprazole and topiramate on free-choice alcohol use. http:\/\/www.clinicaltrials.gov\/show\/NCT00884884\u00a0; 2009 [Acc\u00e8s au site le 11\/06\/2014]."},{"key":"10.1016\/j.lpm.2014.02.030_bib0215","unstructured":"ClinicalTrials.gov Identifier: NCT00769158. Combining medications for the treatment of alcohol dependence: an inpatient preliminary study. http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00769158; 2012 [Acc\u00e8s au site le 11\/06\/2014]."},{"key":"10.1016\/j.lpm.2014.02.030_bib0220","unstructured":"ClinicalTrials.gov Identifier: NCT00006205. Alcohol dependency study: combining medication treatment for alcoholism. http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00006205?term=Addiction&recr=Open&lup_s=01\u00a0%2F15\u00a0%2F2013&lup_d=360; 2013 [Acc\u00e8s au site le 11\/06\/2014]."},{"key":"10.1016\/j.lpm.2014.02.030_bib0225","unstructured":"ClinicalTrials.gov Identifier: NCT00862563. Interdisciplinary study of two novel anticonvulsants in alcoholism. http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00862563; 2013 [Acc\u00e8s au site le 11\/06\/2014]."},{"key":"10.1016\/j.lpm.2014.02.030_bib0230","unstructured":"ClinicalTrials.gov Identifier: NCT01408641. Topiramate for alcohol use in posttraumatic stress disorder. http:\/\/www.clinicaltrials.gov\/show\/NCT01408641; 2012 [Acc\u00e8s au site le 11\/06\/2014]."},{"key":"10.1016\/j.lpm.2014.02.030_bib0235","unstructured":"ClinicalTrials.gov Identifier: NCT01087736. Topiramate treatment of alcohol use disorders in veterans with post traumatic stress disorder (PTSD): a pilot controlled trial of augmentation therapy (TAP). http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01087736?recr=Open&state3=NA%3AUS%3ACA&lup_s=02\u00a0%2F15\u00a0%2F2010&lup_d=30; 2014 [Acc\u00e8s au site le 11\/06\/2014]."},{"key":"10.1016\/j.lpm.2014.02.030_bib0240","unstructured":"ClinicalTrials.gov Identifier: NCT01749215. A controlled trial of topiramate treatment for alcohol dependence in veterans with PTSD (TAP2). http:\/\/clinicaltrials.gov\/show\/NCT01749215; 2014 [Acc\u00e8s au site le 11\/06\/2014]."},{"key":"10.1016\/j.lpm.2014.02.030_bib0245","unstructured":"ClinicalTrials.gov Identifier: NCT00572117. Adjunctive topiramate for treatment of alcohol dependence in patients with bipolar disorder. http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00572117; 2012 [Acc\u00e8s au site le 11\/06\/2014]."},{"key":"10.1016\/j.lpm.2014.02.030_bib0250","unstructured":"ClinicalTrials.gov Identifier: NCT00550394. Efficacy and tolerability of topiramate in treatment of bipolar mania and alcohol use in adolescents and young adults. http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00550394; 2013 [Acc\u00e8s au site le 11\/06\/2014]."},{"key":"10.1016\/j.lpm.2014.02.030_bib0255","unstructured":"ClinicalTrials.gov Identifier: NCT00300742. Topiramate for the treatment of alcohol dependent binge-eating disordered individuals. http:\/\/www.clinicaltrials.gov\/show\/NCT00300742; 2012 [Acc\u00e8s au site le 11\/06\/2014]."},{"key":"10.1016\/j.lpm.2014.02.030_bib0260","unstructured":"ClinicalTrials.gov Identifier: NCT01764685. Topiramate to reduce heavy drinking in hiv-positive heavy drinkers. http:\/\/www.clinicaltrials.gov\/show\/NCT01764685; 2013 [Acc\u00e8s au site le 11\/06\/2014]."},{"key":"10.1016\/j.lpm.2014.02.030_bib0265","unstructured":"ClinicalTrials.gov Identifier: NCT00755716. Topiramate Alone and in combination with the nicotine patch for smoking cessation: a pilot study. http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00755716; 2012 [Acc\u00e8s au site le 11\/06\/2014]."},{"key":"10.1016\/j.lpm.2014.02.030_bib0270","unstructured":"ClinicalTrials.gov Identifier: NCT00208858. A pilot study of the neural correlates of treatment effect on nicotine craving. http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00208858; 2006 [Acc\u00e8s au site le 11\/06\/2014]."},{"key":"10.1016\/j.lpm.2014.02.030_bib0275","unstructured":"ClinicalTrials.gov Identifier: NCT01811940. Multicenter trial of combined pharmacotherapy to treat cocaine dependence (TACT2). http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01811940; 2014 [Acc\u00e8s au site le 11\/06\/2014]"},{"key":"10.1016\/j.lpm.2014.02.030_bib0280","unstructured":"ClinicalTrials.gov Identifier: NCT00448825. Novel pharmacotherapy for dual dependence. http:\/\/www.clinicaltrials.gov\/show\/NCT00448825; 2013 [Acc\u00e8s au site le 11\/06\/2014]."},{"key":"10.1016\/j.lpm.2014.02.030_bib0285","unstructured":"ClinicalTrials.gov Identifier: NCT01182766. New treatment for alcohol and nicotine dependence. http:\/\/www.clinicaltrials.gov\/show\/NCT01182766; 2014 [Acc\u00e8s au site le 11\/06\/2014]."},{"key":"10.1016\/j.lpm.2014.02.030_bib0290","unstructured":"ClinicalTrials.gov Identifier: NCT00802412. Topiramate to aid smoking cessation in alcohol dependent men. http:\/\/www.clinicaltrials.gov\/show\/NCT00802412; 2014 [Acc\u00e8s au site le 11\/06\/2014]."},{"key":"10.1016\/j.lpm.2014.02.030_bib0295","unstructured":"ClinicalTrials.gov Identifier: NCT01110434. Biobehavioral effects of topiramate on cannabis-related outcomes in adolescents. http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01110434; 2012 [Acc\u00e8s au site le 11\/06\/2014]."},{"key":"10.1016\/j.lpm.2014.02.030_bib0300","unstructured":"ClinicalTrials.gov Identifier: NCT00393978. Efficacy study of quetiapine plus topiramate for reducing cannabis consumption and bipolar mania. http:\/\/www.clinicaltrials.gov\/show\/NCT00393978; 2014 [Acc\u00e8s au site le 11\/06\/2014]."},{"key":"10.1016\/j.lpm.2014.02.030_bib0305","unstructured":"ClinicalTrials.gov Identifier: NCT00768677. Topiramate for binge eating disorder among adolescents. http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00768677; 2014 [Acc\u00e8s au site le 11\/06\/2014]."},{"key":"10.1016\/j.lpm.2014.02.030_bib0310","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1176\/appi.psy.46.6.503","article-title":"Delirium associated with baclofen withdrawal: a review of common presentations and management strategies","volume":"46","author":"Leo","year":"2005","journal-title":"Psychosomatics"},{"key":"10.1016\/j.lpm.2014.02.030_bib0315","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1136\/bmj.323.7317.870b","article-title":"Withdrawal of baclofen may cause acute confusion in elderly patients","volume":"323","author":"O\u2019Rourke","year":"2001","journal-title":"BMJ"},{"key":"10.1016\/j.lpm.2014.02.030_bib0320","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1097\/JCP.0b013e3181fb7b97","article-title":"Behavioral disinhibition with baclofen","volume":"30","author":"Soufia","year":"2010","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.lpm.2014.02.030_bib0325","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.biopsych.2012.08.004","article-title":"Addiction therapeutics: obstacles and opportunities","volume":"72","author":"Skolnick","year":"2012","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.lpm.2014.02.030_bib0330","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1093\/alcalc\/agr083","article-title":"Is controlled drinking an acceptable goal in the treatment of alcohol dependence? A survey of French alcohol specialists","volume":"46","author":"Luquiens","year":"2011","journal-title":"Alcohol"},{"issue":"Suppl 1","key":"10.1016\/j.lpm.2014.02.030_bib0335","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1360-0443.2010.03326.x","article-title":"Epidemiology and alcohol policy in Europe","volume":"106","author":"Rehm","year":"2011","journal-title":"Addiction"},{"key":"10.1016\/j.lpm.2014.02.030_bib0340","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1177\/0269881113495320","article-title":"Reduced-risk drinking as a viable treatment goal in problematic alcohol use and alcohol dependence","volume":"27","author":"van Amsterdam","year":"2013","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.lpm.2014.02.030_bib0345","article-title":"Practice Guideline for the treatment of patients with eating disorders, 3rd Edition","author":"Yager","year":"2006","journal-title":"Am J Psy"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498214003091?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498214003091?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:03:33Z","timestamp":1760105013000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498214003091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":69,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S0755498214003091"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2014.02.030","relation":{},"ISSN":["0755-4982"],"issn-type":[{"type":"print","value":"0755-4982"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Le topiramate a-t-il un int\u00e9r\u00eat en addictologie\u00a0?","name":"articletitle","label":"Article Title"},{"value":"La Presse M\u00e9dicale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2014.02.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}